Meta Platforms Inc., aka Mark Zuckerberg’s tech giant behind social media giants like Facebook and Instagram, has chosen to ignore advice from its ethics watchdog regarding how the platform manages posts connected to psychedelics.

The drama dates back to a 2022 “paid partner” post that promoted a ketamine treatment as a “medicine” and a “magical entry into another dimension,” Bloomberg reports. The post yo-yoed on the platform, like a law implemented, then overturned, then reinstated, depending on which party is in the White House. 

Ketamine, discovered in 1956 and approved in 1970, is a dissociative anesthetic with psychedelic traits. It first became famous in battlefield settings like Vietnam for its ability to maintain stable blood flow, gaining a reputation as a safer anesthetic than opioids and being listed on the World Health Organization’s List of Essential Medicines. Besides being an alternative to opiates, recent studies highlight its potential for treating depression, PTSD, and other mental health conditions, making it the only legal psychedelic medicine at the federal level. While it can certainly help transform someone’s life, the drama boils down to whether it’s a good idea to promote it as a medicine that could provide a magical entry into another dimension. Is that just a nice way to describe a medically induced k-hole, or is it irresponsible for IG to allow it to be posted?

Fast forward to August of 2023, and Meta’s Oversight Board didn’t just overturn Meta’s decision to keep the post alive, but also used it as a jumping off point for more sweeping recommendations. The board expressed concerns over what they termed “inconsistently enforced” guidelines about the selling or promoting of substances that sit in the gray areas of legal medicine and recreational fun, such as ketamine, which doctors prescribe off-label for depression and other mental health conditions.  

However, despite members of the psychedelics community believing that Meta is far too strict, censoring content, they responded to the board’s recommendation with resistance. While they agreed to the board’s suggestions regarding clarifying “paid partnerships,” they chose to ignore the stricter guidance on users posting about ketamine and other psychedelic medicines.

Regarding the audit that the board’s been championing, Meta used the tried-and-tried technique of procrastination. They responded that they would “assess the feasibility” in 2024, responding that their current “machine-learning automation” already does a good job at flagging potentially dangerous content in violation with their boundaries.

Meta’s surprising but welcome (for the psychedelics community) decision came after input from about 15 different parties, including Mindbloom, the telehealth company that prescribes ketamine at-home. Mindbloom has been lobbying for Meta to chill and allow posts containing psychedelic content. But the board isn’t happy.

“The board is concerned about inconsistent enforcement of Meta’s policies with regards to pharmaceutical and non-medical drugs,” Dan Chaison, an Oversight Board spokesperson, said in an email, writes Bloomberg. “It stands by its recommendation that Meta should clarify the policy language around content that admits to using or promoting pharmaceutical drugs. The board will closely monitor Meta’s progress toward the recommendations from this case.”

The standing policy permits content that “admits to using or promotes the use of pharmaceutical drugs,” even if it might induce a “high,” provided it’s framed within a “supervised medical setting.” The board emphasized the need for Meta to be clearer about what this setting entails.

In the past, the Oversight Board, funded by Meta, has tackled topics such as COVID-19 misinformation. But Meta isn’t bound to follow its recommendations, and perhaps felt that sharing information, even magical, about ketamine, is different than allowing people to promote faux remedies for a potentially fatal illness such as COVID-19. Companies such as Mindbloom would have lost out on opportunities to promote their mail-order ketamine services. Michael Petegorsky, Mindbloom’s General Counsel, expressed, “This decision is a big win for people who use ketamine therapy and other psychedelic medicines.” He believes it paves the way for individuals to “speak freely about these emerging mental-health treatments using their own words, and without revealing private health information.

However, playing devil’s advocate, as the research behind ketamine’s use for depression is still rolling in, there are those who would make the case that posts calling ketamine magical for depression, which is also a deadly disease, is also irresponsible. Ketamine’s side effects vary based on factors like dosage and how it’s taken. Generally speaking, users might experience feelings of being out of their body, dizziness, altered perceptions, and euphoria (which is usually welcome). Nausea and vomiting are among the most reported negative side effects. While overdosing on ketamine is rare, people must be careful to avoid activities like driving post-intake. Notable, excessive consumption can lead to bladder, urinary, and kidney issues. Responsible providers will share all of this information with patients before they begin treatment, but as it exists in a legal gray area, and considering that not all medical providers have their patient’s best interest at heart, deciding how and where ketamine should be promoted as a treatment for depression and other mental health conditions is sure to be a continued hot topic not just for Meta, but for the psychedelic community. 

The post Meta Sidesteps Ethics Board Recommendations on Drug Content Monitoring appeared first on High Times.

The post Meta Sidesteps Ethics Board Recommendations on Drug Content Monitoring appeared first on Paradise Found.

A few Mississippi dispensaries were ready to open to customers on Jan. 25. Mississippi Trade Association Executive Director Melvin C. Robinson stood outside one of the state’s licensed dispensaries, The Cannabis Company, to welcome customers. “It’s a very exciting day today. History has been made in Brookhaven,” Robinson said.

The first customer at Brookhaven-based The Cannabis Company was Debbie McDermott. “I do suffer from chronic pain and I have some other issues,” she said about why she became a medical cannabis cardholder. The dispensary experienced a setback due to issues with the METRC point-of-sale system, which caused a two-and-a-half-hour delay before McDermott could purchase her medicine.

The Cannabis Company co-owner Le Anne Penn told The Daily Leader that she changed her career to enter the cannabis industry. “It has been a fun journey. I have enjoyed it. The business will be different from what I was doing before,” Penn said. “I was a body technician for 40 years. I decided to pursue this because I saw the potential in the industry and the need in people. Hopefully this will help people who need it or can’t take opioids or other medicines.”

Other news outlets reported dispensaries selling on Jan. 25 as well, with more expecting to receive their shipments over the weekend.

According to Mississippi Medical Marijuana Association Executive Director Ken Newburger, the launch of this program has been a long time coming. “We have been working since 2018 to get medical marijuana in the hands of patients in Mississippi, and it’s surreal to see it finally come to fruition,” said Newburger. “This is only the beginning. More and more businesses will be harvesting, testing, and getting their products on the shelves in the coming months; therefore, more patients will have access to this medicine at certified businesses all across the state.”

Medical cannabis cardholders may purchase up to 3.5 grams per day, six days a week, or a total of 3 ounces every month. Currently, the state allows patients to use medical cannabis if they suffer from one of the approved qualifying conditions. This includes a total of 20 conditions,  such as cancer, Parkinson’s disease, glaucoma, Crohn’s disease, autism, and muscular dystrophy. In addition to that, six more conditions and symptoms qualify as well, including wasting syndrome, severe or intractable nausea, seizures, and severe and persistent muscle spasms, such as those experienced with multiple sclerosis.

Voters originally approved medical cannabis during the election in November 2020 with Initiative 65. In April 2021, the Mississippi Supreme Court allowed opponents of medical cannabis legalization to challenge the vote results, which led to the court striking down Initiative 65 in May, stating that it was constitutionally flawed. Legislators continued to discuss medical cannabis throughout the year, and by September they made a move to re-implement a plan to legalize medical cannabis.

Mississippi Gov. Tate Reeves stalled the progress of a new medical cannabis bill in November 2021, but he finally agreed to the details of a new law in January 2022, and signed it in February. “There is no doubt that there are individuals in our state who could do significantly better if they had access to medically prescribed doses of cannabis,” Reeves said in a press statement. “There are also those who really want a recreational marijuana program that could lead to more people smoking and less people working, with all of the societal and family ills that that brings.”

In October 2022, the state has issued provisional licenses to 491 work permits, 138 dispensaries, 47 cultivators, eight processors, four transportation businesses, three “disposal companies,” and two testing facilities. 

As of December 2022, more than 2,311 applications were submitted, with 1,321 approved, and 990 still being processed. As of Jan. 23, more than 1,700 patients have been approved.

The post Mississippi Celebrates Launch of Medical Cannabis Sales appeared first on High Times.

The post Mississippi Celebrates Launch of Medical Cannabis Sales appeared first on Paradise Found.

The post Mississippi Advocate Demands Cannabis Access: An Exclusive with Amy Smoot appeared first on Paradise Found.